The FDA has approved 3 applications for generics of fingolimod (Gilenya, Novartis). These are the first generics of the drug, which treats [...]
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLiveâ„¢, a multimedia platform dedicated to providing health care professionals treating [...]
Our dear friend and colleague Alan Mandel passed away early Monday morning, November 4, 2019. He fought hard in his battle against PML and [...]
Several organizations have expressed interest and published guidelines or consensus statements emphasizing the need for palliative care for [...]
East Hanover, NJ. October 7, 2019. With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of [...]
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]